Toxicity of external beam accelerated partial-breast
irradiation (APBI) in adjuvant therapy of early-stage breast
cancer: prospective randomized study

CSLog in Log in (EduId)

Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of ...

Přehled o publikaci

J 2024

Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study

BURKOŇ, Petr, Iveta SELINGEROVÁ, Marek SLÁVIK, Miloš HOLÁNEK, Miroslav VRZAL et. al.

Basic information

Original name

Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study

Authors

BURKOŇ, Petr, Iveta SELINGEROVÁ, Marek SLÁVIK, Miloš HOLÁNEK, Miroslav VRZAL, Oldřich COUFAL, Kateřina POLÁCHOVÁ, Petr MULLER, Pavel ŠLAMPA and Tomáš KAZDA

Edition

Radiation Oncology, BMC, Elsevier, 2024, 1748-717X

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Lékařská fakulta – Repository – Repository

DOI

http://dx.doi.org/10.1186/s13014-024-02412-x

UT WoS

001155905200001

EID Scopus

2-s2.0-85184096089

Keywords in English

Early breast cancer; Adjuvant radiotherapy; Surgical bed; APBI; External beam radiotherapy

Links

LX22NPO5102, research and development project. BBMRI.cz IV, large research infrastructures. CZECRIN IV, large research infrastructures.

Changed: 15/3/2025 00:51, RNDr. Daniel Jakubík

Abstract

V originále

gt;= 2 late skin toxicity was observed (p = 0.026). Late toxicity in the breast area (deformation, edema, fibrosis, and pain), affecting the quality of life and cosmetic effect, occurred in 61% and 17% of patients in WBI and APBI arms, respectively. The cosmetic effect was more favorable in the APBI arm, especially 6 to 12 months after the radiotherapy.ConclusionExternal APBI demonstrated better feasibility and less toxicity than the standard regimen in the adjuvant setting for treating early breast cancer patients. The presented study confirmed the level of evidence for establishing the external APBI in daily clinical practice.Trial registrationNCT06007118.

Files attached

https://is.muni.cz/publication/2409840/Toxicity_of_external_beam_accelerated_partial-breast_irradiation__APBI__in_adjuvant_therapy_of_early-stage_breast_cancer_prospective_randomized_study.pdf

Cite

BURKOŇ, Petr, Iveta SELINGEROVÁ, Marek SLÁVIK, Miloš HOLÁNEK, Miroslav VRZAL, Oldřich COUFAL, Kateřina POLÁCHOVÁ, Petr MULLER, Pavel ŠLAMPA and Tomáš KAZDA. Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study. Radiation Oncology. BMC: Elsevier, 2024, vol. 19, No 1, p. 1-12. ISSN 1748-717X. Available from: https://dx.doi.org/10.1186/s13014-024-02412-x.

@article{61577,
   author = {Burkoň, Petr and Selingerová, Iveta and Slávik, Marek and Holánek, Miloš and Vrzal, Miroslav and Coufal, Oldřich and Poláchová, Kateřina and Muller, Petr and Šlampa, Pavel and Kazda, Tomáš},
   article_location = {BMC},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13014-024-02412-x},
   keywords = {Early breast cancer; Adjuvant radiotherapy; Surgical bed; APBI; External beam radiotherapy},
   language = {eng},
   issn = {1748-717X},
   journal = {Radiation Oncology},
   title = {Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study},
   url = {https://ro-journal.biomedcentral.com/articles/10.1186/s13014-024-02412-x},
   volume = {19},
   year = {2024}
}

TY  - JOUR
ID  - 61577
AU  - Burkoň, Petr - Selingerová, Iveta - Slávik, Marek - Holánek, Miloš - Vrzal, Miroslav - Coufal, Oldřich - Poláchová, Kateřina - Muller, Petr - Šlampa, Pavel - Kazda, Tomáš
PY  - 2024
TI  - Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study
JF  - Radiation Oncology
VL  - 19
IS  - 1
SP  - 1-12
EP  - 1-12
PB  - Elsevier
SN  - 1748-717X
KW  - Early breast cancer
KW  - Adjuvant radiotherapy
KW  - Surgical bed
KW  - APBI
KW  - External beam radiotherapy
UR  - https://ro-journal.biomedcentral.com/articles/10.1186/s13014-024-02412-x
N2  - gt;= 2 late skin toxicity was observed (p = 0.026). Late toxicity in the breast area (deformation, edema, fibrosis, and pain), affecting the quality of life and cosmetic effect, occurred in 61% and 17% of patients in WBI and APBI arms, respectively. The cosmetic effect was more favorable in the APBI arm, especially 6 to 12 months after the radiotherapy.ConclusionExternal APBI demonstrated better feasibility and less toxicity than the standard regimen in the adjuvant setting for treating early breast cancer patients. The presented study confirmed the level of evidence for establishing the external APBI in daily clinical practice.Trial registrationNCT06007118.
ER  -

BURKOŇ, Petr, Iveta SELINGEROVÁ, Marek SLÁVIK, Miloš HOLÁNEK, Miroslav VRZAL, Oldřich COUFAL, Kateřina POLÁCHOVÁ, Petr MULLER, Pavel ŠLAMPA and Tomáš KAZDA. Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study. \textit{Radiation Oncology}. BMC: Elsevier, 2024, vol.~19, No~1, p.~1-12. ISSN~1748-717X. Available from: https://dx.doi.org/10.1186/s13014-024-02412-x.